The World Health Organization (WHO) has published its first global research agenda to combat antimicrobial resistance (AMR) that outlines 40 research priorities. An estimated 4.95 million deaths were associated with bacterial AMR in 2019. AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to antimicrobial medicines making infections harder […] Continue reading ->
One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading ->
More R&D into already known emerging disease threats, from Mpox to Lassa fever would go a long way to both bolster developing countries’ preparedness as well as protecting the world, experts argue. Member state negotiations resume next week over a draft WHO convention on pandemic prevention, preparedness and response – which is supposed to be […] Continue reading ->
 GENEVA – Global health conversations are much deeper at present because everyone has been affected by COVID-19 – and this opens up the possibility of building an “all-of-society” approach before the next pandemic, said Sylvie Brand, the World Health Organization’s (WHO) Director of Epidemic and Pandemic Preparedness and Prevention. “We have seen during this pandemic […] Continue reading ->
A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading ->
The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV). The single-shot vaccine intended for use in adults aged 60 or older represents the culmination of six decades of research to protect the world from RSV. With the green light from the FDA on Wednesday, GSK’s Arexvy vaccine […] Continue reading ->